DHES0815A

a THIOMAB antibody-drug conjugate (TDC) that is comprised of an engineered humanized immunoglobulin G1 (IgG1) monoclonal antibody, MHES0488A, which binds specifically to HER2, conjugated to a novel DNA mono-alkylating agent, pyrrolo(2,1-c)(1,4)benzodiazepine monoamide (PBD-MA), via a stable disulfide-based linker

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Altwerger, Gary: 1 article (11/2021)
2.	Andikyan, Vaagn: 1 article (11/2021)
3.	Azodi, Masoud: 1 article (11/2021)
4.	Bellone, Stefania: 1 article (11/2021)
5.	Bonazzoli, Elena: 1 article (11/2021)
6.	Buza, Natalia: 1 article (11/2021)
7.	Clark, Mitchell: 1 article (11/2021)
8.	Gnutti, Barbara: 1 article (11/2021)
9.	Guglielmi, Adele: 1 article (11/2021)
10.	Harold, Justin: 1 article (11/2021)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2021 - "DHES0815A is both highly selective and toxic to USC tumors overexpressing HER2/neu both in vitro and in vivo. " 11/01/2021 - "DHES0815A did not induce significant bystander killing of HER2/neu negative tumors when admixed with HER2/neu positive tumors. " 11/01/2021 - "DHES0815A is a novel antibody-drug-conjugate (ADC) which binds specifically to HER2 overexpressing tumors at a distinct epitope from that bound by trastuzumab and pertuzumab after which it delivers the toxic payload, PBD-MA, a DNA mono-alkylating agent. "
2.	Carcinoma (Carcinomatosis) 11/01/2021 - "DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo."

Related Drugs and Biologics

1.	A-Form DNA (A-DNA)
2.	Immunoconjugates (Immunoconjugate)
3.	Epitopes
4.	Alkylating Agents
5.	Trastuzumab (Herceptin)
6.	pertuzumab